[ad_1]
The daily average of deaths from the new coronavirus fell the most in the last week and reached its lowest rate since May, with 158 deaths (compared to the previous week, at 181). The fall corresponds to 14%.
The announcement was made in an interview with journalists held in Palácio dos Bandeirantes on Friday (25).
The number of daily cases also decreased by 2%, with an average of 1,110 new cases per day.
The ICU bed occupancy rate reached the lowest rate last Monday (21) and presented a further reduction this Friday (25), reaching 46.3% in São Paulo and 45.3% in Greater São Paulo .
The update of the coronavirus data in the state indicates that 6,681 new cases and 200 new deaths were confirmed.
Governor João Doria (PSDB) announced on September 30 the end of the activities of the Ibirapuera field hospital, the last hospital built for this purpose that continues to operate in the capital.
For Jean Gorinchteyn, secretary of state health, the drop in the number of deaths and daily cases and new admissions represents a relief to end the activities of the hospitals exclusively for the coronavirus. “With these indices, we can ensure that hospitals that focus exclusively on treating Covid-19 can be closed, such as the Ibirapuera field hospital itself.”
On Wednesday (23), the governor announced that the first groups of health professionals in the state should be vaccinated against the new coronavirus in the second half of December.
Also according to Doria, in October the first 5 million doses of CoronaVac will arrive in São Paulo, a vaccine produced by the Sinovac Laboratory in alliance with the Butantã Institute. The immunizer will be stored until the Brazilian health authorities approve its application.
Also on Wednesday (23), Anvisa announced the authorization to expand the phase 3 clinical trial of CoronaVac from 9,000 to 13,000 volunteers. The government also increased the number of testing centers from 12 to 16. The new centers are in Barretos (SP), Campo Grande (MS), Cuiabá (MT) and Pelotas (RS).
Dimas Tadeu Covas, director of the Butantan Institute, said that with this expansion of volunteers, it is likely that the institute will reach the minimum number of Covid-19 cases needed in the cohort of 61 cases to perform the so-called “first interim analysis”.
“This expansion helps to obtain the expected results. If the proportions are maintained [de casos esperados no grupo de voluntários que receberam o placebo versus o grupo que recebeu o imunizante]We will have the first results on October 15. If this minimum number is not reached by this date, we can expect the first 154 cases by the end of October, which would demonstrate the effectiveness of at least 50% of the vaccine ”.
Covas also said that if these predictions continue as expected, the government may proceed with registering CoronaVac with Anvisa in November, so that the vaccine will be available for use in December.
